Clinicopathological characteristics of CLL patients used in this study
| Patient no. . | Age, y . | Sex . | Stage* . | VH gene status† . | CD38% . | Cytogenetic . | Ratio total Aiolos/Abl (mRNA) . |
|---|---|---|---|---|---|---|---|
| 1 | 67 | M | A | M | 0 | 13q− (mono), 11q− | 1.99 |
| 2 | 74 | F | B | M | 1 | ND | 3.72 |
| 3 | 60 | M | A | M | 0 | N | 4.06 |
| 4 | 42 | M | A | M | 2 | N | 3.79 |
| 5 | 64 | F | A | M | 1 | ND | 4.66 |
| 6 | 70 | F | A | M | 1 | 13p−, 13q− (bi) | 4.07 |
| 7 | 51 | F | C | M | 3 | N | 3.66 |
| 8 | 60 | M | A | M | 2 | N | 3.84 |
| 9 | 59 | M | B | M | 0 | 6q−, 13q− (bi), + 8 | 5.4 |
| 10 | 75 | M | C | M | 93 | ND | 3.37 |
| 11 | 70 | F | A | U | 72 | + 12 | 4.28 |
| 12 | 54 | M | C | U | 2 | + 12 | 3.63 |
| 13 | 51 | M | A | M | 84 | + 12 | 3.87 |
| 14 | 69 | M | B | M | 2 | ND | 3.9 |
| 15 | 49 | M | B | U | 0 | 13q− (mono), 11q− | 4.58 |
| 16 | 60 | F | B | U | 91 | 13q−, t(8;8) | 5.36 |
| 17 | 59 | F | C | U | 88 | Normal FISH | 4.14 |
| 18 | 58 | M | A | M | 20 | 13q− mono | 2.73 |
| 19 | 60 | M | C | U | 70 | ND | ND |
| 20 | 54 | M | B | ND | 41 | 13q− (mono) | 4.87 |
| 21 | 45 | M | B | M | 37 | Normal FISH | 2.84 |
| 22 | 56 | M | A | ND | 30 | ND | 3.45 |
| 23 | 80 | M | B | U | 71 | del 13q | 2.93 |
| 24 | 65 | F | A | M | 0 | ND | 4.2 |
| 25 | 65 | M | ND | ND | 97 | ND | 4.41 |
| 26 | 80 | M | A | ND | 91 | + 12 | 3.06 |
| 27 | 60 | F | C | U | 90 | + 12 | 3.98 |
| 28 | 77 | F | A | U | 1 | 13q−, t(2;18), t(6;13) | 2.53 |
| 29 | 62 | F | A | ND | 1 | N | 3.87 |
| 30 | 87 | F | A | ND | 0 | 13q− (mono) | 3.22 |
| 31 | 79 | M | A | M | 56 | 13q− (mono) | 2.32 |
| 32 | 62 | M | A | M | 0 | 13q− (mono) | 3.42 |
| 33 | 78 | M | A | M | 0 | 13q− (mono), t(9; 13; 14) | 3.37 |
| 34 | 67 | M | B | M | ND | N | ND |
| 35 | 75 | F | A | M | ND | ND | ND |
| 36 | 63 | M | A | U | ND | 13q−, 11q− | ND |
| 37 | 78 | M | A | M | 1 | ND | ND |
| 38 | 74 | M | B | U | 28 | 13q− | ND |
| 39 | 77 | M | B | U | 1 | 13q−, 11q− | ND |
| 40 | 50 | M | A | M | 0 | 13q− | ND |
| 41 | 79 | F | A | ND | ND | ND | ND |
| 42 | 80 | M | A | M | 56 | ND | ND |
| 43 | 66 | M | A | M | 2 | N | ND |
| 44 | 64 | M | A | M | 1 | ND | ND |
| Patient no. . | Age, y . | Sex . | Stage* . | VH gene status† . | CD38% . | Cytogenetic . | Ratio total Aiolos/Abl (mRNA) . |
|---|---|---|---|---|---|---|---|
| 1 | 67 | M | A | M | 0 | 13q− (mono), 11q− | 1.99 |
| 2 | 74 | F | B | M | 1 | ND | 3.72 |
| 3 | 60 | M | A | M | 0 | N | 4.06 |
| 4 | 42 | M | A | M | 2 | N | 3.79 |
| 5 | 64 | F | A | M | 1 | ND | 4.66 |
| 6 | 70 | F | A | M | 1 | 13p−, 13q− (bi) | 4.07 |
| 7 | 51 | F | C | M | 3 | N | 3.66 |
| 8 | 60 | M | A | M | 2 | N | 3.84 |
| 9 | 59 | M | B | M | 0 | 6q−, 13q− (bi), + 8 | 5.4 |
| 10 | 75 | M | C | M | 93 | ND | 3.37 |
| 11 | 70 | F | A | U | 72 | + 12 | 4.28 |
| 12 | 54 | M | C | U | 2 | + 12 | 3.63 |
| 13 | 51 | M | A | M | 84 | + 12 | 3.87 |
| 14 | 69 | M | B | M | 2 | ND | 3.9 |
| 15 | 49 | M | B | U | 0 | 13q− (mono), 11q− | 4.58 |
| 16 | 60 | F | B | U | 91 | 13q−, t(8;8) | 5.36 |
| 17 | 59 | F | C | U | 88 | Normal FISH | 4.14 |
| 18 | 58 | M | A | M | 20 | 13q− mono | 2.73 |
| 19 | 60 | M | C | U | 70 | ND | ND |
| 20 | 54 | M | B | ND | 41 | 13q− (mono) | 4.87 |
| 21 | 45 | M | B | M | 37 | Normal FISH | 2.84 |
| 22 | 56 | M | A | ND | 30 | ND | 3.45 |
| 23 | 80 | M | B | U | 71 | del 13q | 2.93 |
| 24 | 65 | F | A | M | 0 | ND | 4.2 |
| 25 | 65 | M | ND | ND | 97 | ND | 4.41 |
| 26 | 80 | M | A | ND | 91 | + 12 | 3.06 |
| 27 | 60 | F | C | U | 90 | + 12 | 3.98 |
| 28 | 77 | F | A | U | 1 | 13q−, t(2;18), t(6;13) | 2.53 |
| 29 | 62 | F | A | ND | 1 | N | 3.87 |
| 30 | 87 | F | A | ND | 0 | 13q− (mono) | 3.22 |
| 31 | 79 | M | A | M | 56 | 13q− (mono) | 2.32 |
| 32 | 62 | M | A | M | 0 | 13q− (mono) | 3.42 |
| 33 | 78 | M | A | M | 0 | 13q− (mono), t(9; 13; 14) | 3.37 |
| 34 | 67 | M | B | M | ND | N | ND |
| 35 | 75 | F | A | M | ND | ND | ND |
| 36 | 63 | M | A | U | ND | 13q−, 11q− | ND |
| 37 | 78 | M | A | M | 1 | ND | ND |
| 38 | 74 | M | B | U | 28 | 13q− | ND |
| 39 | 77 | M | B | U | 1 | 13q−, 11q− | ND |
| 40 | 50 | M | A | M | 0 | 13q− | ND |
| 41 | 79 | F | A | ND | ND | ND | ND |
| 42 | 80 | M | A | M | 56 | ND | ND |
| 43 | 66 | M | A | M | 2 | N | ND |
| 44 | 64 | M | A | M | 1 | ND | ND |
Abl indicates Abelson; bi, biallelic; CLL, chronic lymphocytic leukemia; FISH, fluorescence in situ hybridization; M, mutated; mono, monoallelic; N, normal; ND, not determined; t, translocation; U, unmutated; + 12, trisomy 12; 13q−, deletion 13q; 13p−, deletion 13p; 11q−, deletion 11q; and 6q−, deletion 6q.
Stage is according to Binet scale.
Greater than 2% deviation from germline sequence was considered as mutated. In our study, ZAP-70 negative cases are IgVH mutated. The average age for HD is ∼ 54 and ∼ 64 for CLL patients. The average of ratio total Aiolos/Abl for HD is ∼ 2.4.